Accepted for Publication: February 17, 2015.
Published Online: April 20, 2015. doi:10.1001/jamaneurol.2015.0203.
Study concept and design: Rodríguez Cruz, Al-Hajjar, Beeson, Vincent, Leite, Palace.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Rodríguez Cruz, Al-Hajjar, Vincent, Palace.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Rodríguez Cruz.
Administrative, technical, or material support: Huda, Jacobson, Woodhall, Beeson.
Study supervision: Vincent, Palace.
Conflict of Interest Disclosures: Dr Rodríguez Cruz reported being supported by the National Health Service National Specialised Commissioning Group for Congenital Myasthenia. Dr Huda reported being supported by a Watney, Myasthenia Gravis Association, and Oxford Biomedical Research Centre fellowship. Ms Buckley reported receiving research support from the Medical Research Council, United Kingdom. Dr Vincent reported serving on scientific advisory boards for the Patrick Berthoud Charitable Trust, the Brain Research Trust, and the Myasthenia Gravis Foundation of America; reported receiving funding for travel and a speaker honorarium from Baxter International, Inc, and Biogen, Idec; reported being an associate editor for Brain; reported earning royalties from the publication of Clinical Neuroimmunology (Blackwell Publishing, 2005) and Inflammatory and Autoimmune Disorders of the Nervous System in Children (Mac Keith Press, 2010); reported obtaining research support from the European Union, National Institute for Health Research Oxford Biomedical Research Centre, Euroimmun AG, and the Sir Halley Stewart Trust; and reported receiving MuSK antibody royalties and consulting fees from Athena Diagnostics, Inc. Dr Leite reported being supported by the National Health Service National Specialised Commissioning Group for Neuromyelitis Optica and by the National Institute for Health Research Oxford Biomedical Research Centre and reported receiving speaking honoraria from Biogen Idec and travel grants from Novartis. Dr Palace reported being partly funded by highly specialized services to run a national congenital myasthenia service and a neuromyelitis optica service; reported receiving support for scientific meetings and honoraria for advisory work from Merck Serono, Biogen Idec, Novartis, Teva, Chugai Pharma, and Bayer Schering and unrestricted grants from Merck Serono, Novartis, Biogen Idec, and Bayer Schering; reported that her hospital trust receives funds for her role as a clinical lead for the United Kingdom Department of Health risk-sharing scheme; reported receiving grants from the National Multiple Sclerosis Society and The Guthie-Jackson Charitable Foundation for unrelated research studies; and reported serving as a board member for the charitable European MS foundation “The Charcot Foundation” and on the steering committee for the European collaborative multiple sclerosis imaging group “Magnetic Resonance Imaging in Multiple Sclerosis.” No other disclosures were reported.